Assessment of [18F]-Fluorocellobiose ([18F]FCB) Pharmacokinetics in Healthy Volunteers and Subjects With Invasive Mold Infections

Inclusion criteria

* INCLUSION CRITERIA: Inclusion Criteria for healthy volunteers (Groups 1 and 2) 1. Male or female \>=18 years of age at the time of consent and imaging. 2. Provision of signed and dated informed consent form. 3. Subjects must have the ability to read, understand and provide written informed consent for the initiation of any study related procedures. Adults lacking capacity will not be enrolled in this study. 4. Stated willingness to comply with all study procedures and availability for the duration of the study. 5. Generally healthy subjects based on medical history, physical examination, and laboratory testing, as determined by the PI. 6. Female participants of childbearing potential must be using a medically acceptable means of contraception. Inclusion Criteria for Patients with PROVEN or PROBABLE Aspergillosis or Mucormycosis Infections (Groups 3a and 3b) 1. Male or female \>=18 years of age at the time of consent and imaging. 2. Provision of signed and dated informed consent form. 3. Subjects must have the ability to read, understand and provide written informed consent for the initiation of any study related procedures. Adults lacking capacity will not be enrolled in this study. 4. Stated willingness to comply with all study procedures and availability for the duration of the study. 5. PROVEN or PROBABLE Invasive fungal disease (IFI), defined by the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (EORTC/MSGERC) \[18\]. 6. Female participants of childbearing potential must be using a medically acceptable means of contraception. For inpatients, they should be determined by the attending of record to be stable to participate in the study (will be documented in the research records). Inclusion Criteria for Participants with Non-Aspergillus/Non-Mucorales Mold Infections (Group 4a) and Participants with Dimorphic Fungal Infections (Group 4b). 1. Male or female \>=18 years of age at the time of consent and imaging. 2. Provision of signed and dated informed consent form. 3. Subjects must have the ability to read, understand and provide written informed consent for the initiation of any study related procedures. Adults lacking capacity will not be enrolled in this study. 4. Stated willingness to comply with all study procedures and availability for the duration of the study. 5. Non-Aspergillus/non-Mucorales mold infections including, but not limited to Cladophialophora spp., Dematiaceous molds (such as Curvularia, Scedosporium spp.) or dimorphic fungi (including, but not limited to Blastomyces spp., Coccidioides spp., Histoplasma spp. and Exophiala spp.). 6. Female participants of childbearing potential must be using a medically acceptable means of contraception. For inpatients, they should be determined by the attending of record to be stable to participate in the study (will be documented in the research records). Acceptable effective method of contraception (birth control) will include: * Partner vasectomy (making sterile) * Bilateral tubal ligation * Intrauterine devices (IUDs) * Hormonal implants (such as Implanon) * Other hormonal methods (birth control pills, injections, patches, vaginal rings)